EXPERIENCE: Is virtual reality suitable to identify differences between depressed and healthy individuals?

ISRCTN ISRCTN16396369
DOI https://doi.org/10.1186/ISRCTN16396369
Secondary identifying numbers 4688
Submission date
15/11/2022
Registration date
29/12/2022
Last edited
17/04/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Current diagnostic protocols for affective disorders such as depression, anxiety and eating disorders are commonly based on self-reports and verbal communication between the patient and the psychiatrist. Thus, an appropriate psychiatric diagnosis is heavily influenced by the patient’s ability to correctly express him or herself, as well as the psychiatrist’s ability to correctly understand and identify said symptoms. In this study, we aim to investigate whether measures based on behaviors and implicit reactions to specific stimuli can be used as diagnostic tools and whether these are comparable to traditional procedures based on self-reports (interviews, questionnaires). For this purpose, we will use an immersive virtual reality (VR) environment where behavioral tasks should be explored and completed in a narrative-driven serious game (SG).
A literature review was conducted with the aim to identify behavioral measures that have the potential to distinguish depressed and healthy individuals in virtual reality. The findings of this review were used to design a specific virtual reality environment for the assessment of these measures and thus the severity of depressive symptoms. The current study aims to test whether this environment and the implemented behavioral measures can differentiate depressed and healthy individuals.

Who can participate?
Adults (18-35 years) who are moderately to severely depressed; and also healthy individuals who are free from any disease/disability that would impair one’s ability to interact in the VR environment requiring the use of a headset and controllers (e.g., blindness, intellectual disability)

What does the study involve?
Participants will be asked to explore the VR environment on their own. A battery of psychometric diagnostic scales will also be administered before and after participants are exposed to the VR environment. Data on engagement with the virtual environment, performance on cognitive tasks and collected and ECG and GSR will be retrieved and analyzed for group level differences and via classification models, and the classification models will be compared to existing psychometric diagnostic scales.

What are the possible benefits and risks of participating?
Possible benefits for participants include getting the chance to try virtual reality. A possible risk of participation is that virtual reality might induce symptoms of cyber sickness.

Where is the study run from?
University of Padua (Italy)

When is the study starting and how long is it expected to run?
January 2022 to May 2023

Who is funding the study?
European Commission H2020 Framework Program (Grant No. 101017727)

Who is the main contact?
1. Claudio Gentili, c.gentili@unipd.it (Italy)
2. Vladimir Carli, vladimir.carli@ki.se (Sweden)

Contact information

Dr Vladimir Carli
Scientific

Granits väg 4
Solna
17177
Sweden

ORCiD logoORCID ID 0000-0001-6922-0675
Phone +46 (0)709354038
Email vladimir.carli@ki.se
Prof Claudio Gentili
Scientific

Via Venezia 8
Padua
35135
Italy

ORCiD logoORCID ID 0000-0002-2579-8755
Phone +39 (0)498276587
Email c.gentili@unipd.it

Study information

Study designSingle-center cross-sectional observational study
Primary study designObservational
Secondary study designCase-control study
Study setting(s)Internet/virtual, University/medical school/dental school
Study typeDiagnostic
Participant information sheet 42769 PIS 26Oct2020.pdf
Scientific titlePilot study on the EXPERIENCE system for the investigation of behavioral differences between depressed and healthy-control participants in Virtual Reality
Study acronymEXPERIENCE
Study hypothesisA battery of behavioral and cognitive measures (RVIP; TMT; 2-back test; WCST; metacognitive sensitivity; curiosity; persistence; engagement with emotionally valenced stimuli; mood induction) embedded within a Virtual Reality serious game (SG) combined with physiological measures (ECG and GSR) can differentiate between individuals with varying levels of depression when analyzed by Machine Learning algorithms.
Ethics approval(s)Approved 10/03/2022, Ethics Committee for Psychological Research at the University of
Padua (Via Venezia 8, 35131, Padova, Italy; +39 (0)498276587; comitato.etico.area17@unipd.it), ref: 4249B85C26A719639545360E3D0D9722
ConditionAssessment of depressive symptom severity
InterventionThe study requires one visit per participant, which includes (1) a pre-VR questionnaire battery, (2) a 20–30-minute engagement with a VR environment, (3) and a post-VR questionnaire battery. All participants receive the same battery and same exposure to VR (regardless of affiliation with the healthy-control or depressed group) and there is no planned follow-up.
After giving informed consent, all participants receive a questionnaire battery on paper. The pre-VR battery is composed of the following:
1. Background questionnaire (e.g., demographic data, diagnosis and medication)
2. Patient Health Questionnaire (PHQ-9)
3. Anxiety component of the Depression Anxiety Stress Scales (DASS-21)
4. Positive and Negative Affect Schedule (PANAS-SF)
5. Curiosity and Exploration Inventory-II (CEI-II)

Hereinafter, all participants fulfilling the criteria for either the healthy-control or the depressed group (assessed based on the answers provided in the pre-VR battery) receive the VR headset and controllers. Participants will be placed in a virtual hallway and receive an audio message that explains the narrative of the scenario. Specifically, they will be expected to explore numerous rooms and they can do so by opening doors by solving tasks. (These tasks are four cognitive tasks: N-back; Rapid Visual Information Processing; Wisconsin Card Sorting Test; and Trail Making Test.) After a tutorial on how to move around in the environment and how the controllers' function, participants reach the first door and have to complete a cognitive task to move forward. After completion, they will be asked to evaluate their own performance on a visual scale and also be asked whether they want to reattempt the task or move forward. Once the door is open, they arrive at a central room, equipped with numerous objects (e.g., table, sofa, bookshelf) and some interactive elements (e.g., boxes, picture frames, buttons). From the central room, there are three more rooms available, each of which is behind a door that requires participants to complete another cognitive task. One of these rooms is equipped with positive and another with negative mood induction – the third is neutral in terms of mood induction. Similarly to the central room, these rooms as well contain various interactive elements (e.g., desk with computer and pens; whiteboard to draw). After having visited all rooms, an exit sign lights up. Participants are free to exist in the environment or go back and spend more time exploring it.

After engagement with the VR environment, a second test battery is administered which includes:
1. Anxiety component of the Depression Anxiety Stress Scales (DASS-21)
2. Positive and Negative Affect Schedule (PANAS-SF)
3. Acceptability questionnaire

Data collected during engagement with the VR environment will be used to train a Machine Learning algorithm for the classification of depressed and non-depressed participants. The algorithm will be informed by current depressive symptoms and prior clinical diagnosis as assessed and registered via the pre-VR test battery.
Intervention typeOther
Primary outcome measurePerformance on four cognitive tasks measured during engagement with the virtual reality environment:
1. Working memory function measured using the N-back task
2. Executive functions and cognitive flexibility measured using the Wisconsin Card Sorting Test
3. Processing speed measured using the Trail Making Test Parts A & B
4. Sustained attention measured using the Rapid Visual Information Processing task
Secondary outcome measuresBehavioral outcomes:
1. Number of interactions with objects and explored areas, and time spent in certain virtual rooms measured during engagement with the virtual reality environment
2. Eye-tracking data measured during engagement with the virtual reality environment
3. Physiological response assessed using electrocardiogram (ECG) measured with an electrocardiograph and galvanic skin response (GSR) measured with electrodes during engagement with the virtual reality environment
4. Metacognitive sensitivity measured using a self-evaluation of performance questionnaire during engagement with the virtual reality environment
5. Persistence measured using the number of tries on cognitive tasks during engagement with the virtual reality environment
Overall study start date01/01/2022
Overall study end date11/05/2023

Eligibility

Participant type(s)Mixed
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants100 (50 per group)
Total final enrolment100
Participant inclusion criteriaPatients with depression:
1. Aged between 18 and 35 years old
2. Active moderate/severe depressive symptoms (a score > 9 on the PHQ-9 scale)
3. No diagnosis of psychiatric disorders other than depressive and anxiety disorders
4. If on current psychological or pharmacological treatment, treatment is stable since at least 4 weeks

Healthy volunteers:
1. Aged between 18 and 35 years old
2. No previous or current diagnosis of mood or anxiety disorder
3. No diagnosis of other psychiatric disorders
4. A score <5 on the PHQ-9 scale
Participant exclusion criteria1. Any disease/disability that would impair one’s ability to interact in the virtual reality environment requiring the use of a headset and controllers (e.g., blindness, intellectual disability)
2. Migraine if prophylactic medication is taken
Recruitment start date24/11/2022
Recruitment end date30/04/2023

Locations

Countries of recruitment

  • Italy

Study participating centre

University of Padua
Department of General Psychology Via Venezia 8
Padua
35135
Italy

Sponsor information

Karolinska Institute
University/education

National Centre for Suicide Research and Prevention
Granits väg 4
Solna
17177
Sweden

Phone +46 (0)852480000
Email nasp@ki.se
Website https://ki.se/en/nasp/national-centre-for-suicide-research-and-prevention
ROR logo "ROR" https://ror.org/056d84691

Funders

Funder type

Government

Horizon 2020
Government organisation / National government
Alternative name(s)
EU Framework Programme for Research and Innovation, Horizon 2020 - Research and Innovation Framework Programme, European Union Framework Programme for Research and Innovation

Results and Publications

Intention to publish date30/06/2025
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination plan1. Planned publication in high-impact peer-reviewed journals
2. Oral communication, primarily at international conferences
IPD sharing planThe datasets generated during and/or analyzed during the current study are not expected to be made available due to lack of ethical approval for a data sharing policy.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 26/10/2020 25/11/2022 No Yes
Results article 16/04/2025 17/04/2025 Yes No

Additional files

42769 PIS 26Oct2020.pdf

Editorial Notes

17/04/2025: Publication reference added.
06/06/2024: The following changes were made:
1. The overall study end date was changed from 30/04/2023 to 11/05/2023.
2. The intention to publish date was changed from 30/06/2024 to 30/06/2025.
3. The total final enrolment was added.
14/02/2023: The study setting has been changed from ‘Other’.
25/11/2022: Trial's existence confirmed by the Ethics Committee for Psychological Research at the University of Padua, Italy.